Erleada (apalutamide) — United Healthcare
Prostate cancer (non-metastatic castration-resistant or metastatic castration-sensitive)
Initial criteria
- Patient is less than 19 years of age OR
- Diagnosis of prostate cancer AND
- EITHER: (Disease is castration-resistant or recurrent AND Disease is non-metastatic) OR (Disease is castration-sensitive or naive AND Disease is metastatic) AND
- EITHER: (Used in combination with a gonadotropin-releasing hormone (GnRH) analog [e.g., Lupron (leuprolide), Zoladex (goserelin), Trelstar (triptorelin), Vantas (histrelin), Firmagon (degarelix)]) OR (Patient has had bilateral orchiectomy)
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Erleada therapy
Approval duration
12 months